Clinical Trial Update: EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial evaluating an EGFR-targeting antibody in combination with a PD-1 inhibitor and chemotherapy for recurrent or metastatic naso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Chemotherapy (chemotherapy)
• EGFR antibody
• PD-1 inhibitor

Snippet

Sponsor: Sun Yat-Sen University Cancer Center | Conditions: Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma | Phase 1, Phase 2 | Status: RECRUITING